Floatz logo

BUSULFANUM

Myelodysplastic/Myeloproliferative Neoplasm

Jacqueline Garcia, MDSmall moleculePhase 2/3Active
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
95/ 100

Competitive context

41 Active assets in the Myelodysplastic/Myeloproliferative Neoplasm cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BBB
CYTARABINE
Fred Hutchinson Cancer Center
Phase 3BBB
MELPHALAN
M.D. Anderson Cancer Center
Phase 2/3BBB
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN, RABBIT
M.D. Anderson Cancer Center
Phase 2/3BBB

View all 50 →

Same molecule, other indications

BUSULFANUM is also rated in:

graft versus host diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →
Fanconi anemiaActive
BBB
Indicative · Phase 2/3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →